solubility of ABT-263 in water, the solubility of ABT-263 in DMSO, the solubility of ABT-263 in PBS buffer, the animal experiment(test) of ABT-263,the in vivo,in vitro and clinical trial test of ABT-263,the cell experiment(test) of ABT-263,the IC50, EC50 and Affinity of ABT-263....
The oral efficacy of ABT-263 should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens.
suggesting that ABT-263 was deleterious in females. A significant interaction between the variables “sex” and “treatment” in the 2-way ANOVA of the discrimination index illustrates an opposite effect of ABT-263 in male and female mice: for short-term discrimination index F(1, 54) = ...
Navitoclax (ABT-263) 是有效,可口服的 Bcl-2 抑制剂,可与Bcl-xL,Bcl-2, Bcl-w等多种Bcl-2家族蛋白结合,Ki 值小于 1 nM.
Navitoclax (ABT-263), a novel, oral Bcl-2 inhibitor, enhances the antitumor effects of chemotherapy in vitro by lowering the apoptotic threshold. This phase I study (NCT01009073) evaluated the safety, pharmacokinetics, and preliminary antitumor activity of navitoclax combined with erlotinib in patient...
To test this likelihood, we treated the HCC cells with either the senolytic agent ABT-263 or lorlatinib, or both ABT-263 and lorlatinib. ABT-263 has been shown to eradicate senescent cells.27 We found that ABT-263 significantly enhanced the efficacy of lorlatinib, as observed by much ...
10, 13, 14 SCLC’s response rates to ABT-263 in early clinical studies have also been quite variable, ranging from minimal tumor shrinkage to progressive disease.14 It was demonstrated that one factor mediating in vitro resistance to ABT-737 was the level of MCL-1 expression.11, 15, 16 ...
Mechanistically, apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo. Conclusions Our study provides a rationale for the clinical application of ...
clinical trialABT-263BCL2navitoclaxWe evaluated the safety and biologic activity of tLeukemia and lymphomaKipps TJ,Eradat H,Grosicki S,et al.A phaseⅡstudy of the BH3 mimetic Bcl-2 inhibitor navitoclax(ABT-263)with or without rituximab,in previously untreated B-cell chronic lymphocytic leukemia...
ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by over